trending Market Intelligence /marketintelligence/en/news-insights/trending/H4mn1H80M1HVDSq8dfKimA2 content esgSubNav
In This List

Masimo noninvasive blood oxygen measurement device approved by US FDA

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Masimo noninvasive blood oxygen measurement device approved by US FDA

Masimo Corp. said the U.S. Food and Drug Administration cleared its Rad-67 device combined with the Spot-check Next Generation SpHb monitoring system and Rainbow DCI sensor to measure the oxygen level in the blood.

Rad-67 is a pulse oximeter, a noninvasive device that measures the fraction of oxygen-carrying hemoglobin to total hemoglobin in the blood. The device also measures methemoglobin, stable oxidized hemoglobin that cannot transfer oxygen to the body's tissues, and a complex of carbon monoxide and hemoglobin called carboxyhemoglobin.

The device also allows for a historical review of the collected data, patient identification and wireless data transfer to electronic medical records. According to the company's March 25 press release, Rad-67 cannot be used for pregnant and pediatric patients as well as those with kidney disease. The device is not a replacement for laboratory blood testing, Masimo said.

The Irvine, Calif.-based healthcare company develops and markets noninvasive monitoring technologies.